Manatuck Hill Partners’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History
Bought
Maintained
Sold
Manatuck Hill Partners's AST.WS Position: Q3 2017 in Review
Manatuck Hill Partners sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 75,000 shares — an estimated $38K sold.
Manatuck Hill Partners first reported a position in AST.WS in Q3 2016 and held it in 4 quarters. The position peaked at $41K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.
- Manatuck Hill Partners reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
- Manatuck Hill Partners sold 75,000 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $38K.
- Manatuck Hill Partners first reported a position in Asterias Biotherapeutics Warrants in Q3 2016 and held it in 4 quarters.
- Manatuck Hill Partners's Asterias Biotherapeutics Warrants position peaked at $41K in Q4 2016.
- 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.
Based on Manatuck Hill Partners's 13F filing for Q3 2017, filed 14 Nov 2017.